Who we are and what we do
Our team at Millendo Therapeutics is primarily focused on developing new treatments for orphan endocrine diseases where there are significant unmet medical needs.
As a leading orphan endocrine disease company, we are committed to pursuing distinct and transformative treatments to address patient needs, as well as those of families, caregivers and healthcare providers.
Founded in 2012, we believe in the ability to leverage scientific advances to develop novel compounds to treat complex conditions and advance clinical care. Our commitment is to develop first-in-class therapies that enable patients, families, and caregivers to live fuller lives.
Board of Directors
Carol Gallagher joined NEA in October 2014. She is primarily focused on making biopharma investments. Carol is a proven entrepreneur, operator and more recently investor with nearly 30 years of experience in commercial, drug development and business development roles. Prior to joining NEA she was a Venture Partner with Frazier Healthcare and she served as an independent director on multiple Boards. From 2008-2011, Carol was president and CEO of Calistoga Pharmaceuticals which developed the first-in-class therapeutic now marketed by Gilead as ZYDELIG.
She currently serves as Chairman of the Board at Millendo Therapeutics, lead director at Atara Bio, and as a director at Annexon, Chromacode, Metacrine, PIONYR Immunotherapeutics, Qpex BioPharma, and Xoc Pharmaceuticals.
Dr. Gallagher attended Vanderbilt University and holds B.S. and Pharm.D. degrees from the College of Pharmacy at the University of Kentucky.
Mr. Dable joined Acceleron in 2016 as the Company’s President and Chief Executive Officer and member of its Board of Directors.
Mr. Dable most recently served as President of U.S. Pharmaceuticals at Bayer AG. During his 22-year tenure there, Mr. Dable held positions of increasing responsibility. In addition to President of U.S. Pharmaceuticals, he also served as Executive Vice President, Global Head Specialty Medicine; Vice President, Ophthalmology, Global Launch Team Head. EYLEA®, Global Head, Neurology and Ophthalmology; Vice President, Regional Head, Hematology and Cardiology; Director of International Sales and Marketing, Biologics Research; and Head of Strategic Planning, Pharmaceuticals, Japan. Mr. Dable’s earlier experience at Bayer AG includes various sales and sales management positions in Canada.
As Executive Vice President, Global Head Specialty Medicine, Mr. Dable led the launch of various blockbuster brands, including EYLEA®, Stivarga®, and Xofigo®. Mr. Dable also managed research and development collaborations and served on Joint Steering Committees with companies such as Algeta ASA, Orion Corporation and Regeneron Pharmaceuticals.
Mr. Dable is currently a member of the Board of Directors of Millendo Therapeutics and recently served on the Board of Directors of the Biotechnology Innovation Organization (BIO).
Mr. Dable received a BBA in Marketing and Finance and his MBA from the University of New Brunswick.
Mary Lynne Hedley, Ph.D. has served as TESARO’s President and was a member of their board of directors since co-founding the company in March 2010; the company was acquired by GlaxoSmithKline plc in January 2019. Dr. Hedley served as Executive Vice President of Operations and Chief Scientific Officer of Abraxis BioScience, a biotechnology company. Dr. Hedley previously served as Executive Vice President of Eisai Corporation of North America following the company’s acquisition of MGI Pharma in January 2008. Prior to its acquisition by Eisai, Dr. Hedley served in various positions at MGI Pharma, including Executive Vice President and Chief Scientific Officer.
Dr. Hedley completed two consecutive postdoctoral fellowships at Harvard University and earned her bachelor of science degree in microbiology from Purdue University and her doctoral degree in immunology from the University of Texas, Southwestern Medical Center. She mentors undergraduate science students at Harvard University and Boston University and also serves on the Board of Directors of Millendo Therapeutics and Youville Place, an assisted living facility. She served on the Board of Directors for Receptos until its its acquisition by Celgene.
Mr. James Hindman has over 30 years of global and strategic senior financial experience in the pharmaceutical, biologics, and medical device industries. He enjoyed a long and esteemed career with Allergan, Inc., starting with the company as Manager of Accounting in 1984 and most recently serving as Executive Vice President of Finance and Business Development and Chief Financial Officer. Under his leadership, Allergan achieved its most robust financial performance in the company’s 64-year history. Mr. Hindman was instrumental in facilitating the largest restructuring and rewiring of Allergan, creating $20B in shareholder value that ultimately led to Actavis’ acquisition of Allergan in 2015 and the creation of one of the top ten global pharmaceutical firms. During his 30-year tenure at Allergan, Mr. Hindman held various senior leadership positions including Executive Vice President of Finance and Business Development and Chief Financial Officer, and Senior Vice President, Finance and Controller, and was responsible for strategic and financial functions including treasury, investor relations, risk, controller, financial reporting, SEC compliance, audits, acquisitions and divestitures, and strategic planning. Additionally, he served as President of the Allergan Foundation from 2009-2015.
Mr. Hindman earned his MBA from Pepperdine University and a B.S. in accounting from Loyola Marymount University. He currently serves as Director of Sienna Biopharmaceuticals (SNNA), a Director of Aatru Medical, Inc. and as a member of the Loyola Marymount University Board of Trustees.
Dr. Howe is a leader in medical diplomacy, health policy, and business focused on strengthening organizations and bringing people together.
In his 14 years as President of Project HOPE, an international health education and humanitarian assistance foundation, Dr. Howe helped triple HOPE’s revenue and promoted health education on a global scale.
Dr. Howe also held the Distinguished Chair in Health Policy and served as Chief Executive at The University of Texas Health Science Center at San Antonio, where he is currently the President Emeritus.
Dr. Howe is board certified in internal medicine and cardiovascular disease and has spent his career advocating for the importance of continued medical research. Throughout his career, Dr. Howe has received numerous honors and awards for his work and service, including the U.S. Army’s Commander’s Award for Public Service, the Award of Excellence from the International Association of Business Communicators, the Surgeon General’s Exemplary Service Award, the Magnolia Award from the City of Shanghai, China, and the Boston University Distinguished Alumni Award.
Dr. Howe has served on numerous boards and councils, and currently is on the board of Boston University, MAXIMUS Federal, and the Mary Christie Foundation (chair and president). He is a graduate of Amherst College, Boston University School of Medicine, and Harvard Business School’s Program in Health System Management, and served two years in the Army Medical Corps.
Geoff Nichol, M.B., Ch.B., M.B.A., has nearly 30 years’ experience in drug development. His first successful drug development success was at SmithKline Beecham with the approval of Augmentin BID in 1996 for adults and children for all indications. As a VP at Novartis 1996-2002, he managed, successively, a clinical development therapeutic area, US Medical Affairs, and Global Project and Portfolio Management, with significant involvement in the Foradil and Xolair programs. Subsequently, 2002-2009, he was SVP of Development at Medarex Inc, where he was responsible for the foundational clinical development of the breakthrough cancer immunotherapy checkpoint inhibitors Yervoy (Phase 1 through Phase 3) and Opdivo (Phase 1) culminating in the acquisition of Medarex by Bristol-Myers Squibb and the award, in 2018, of the Nobel Prize for Medicine and Physiology related to these programs.
From 2011-2016 Geoff was EVP R&D at Sangamo BioSciences, a zinc finger genome editing and gene therapy company. He managed the pre-clinical development of several genome editing IND candidates both in vivo and ex vivo in T cells and hematopoietic stem cells, and an AAV cDNA FVIII gene therapy for hemophilia A, all now in clinical trials.
In 2016 Geoff became CMO at BioMarin, managing an active portfolio of clinical development programs, including the development and approval of Brineura, Palynziq, phase 3 development of BMN 270, a leading gene therapy for hemophilia A, BMN 111, a groundbreaking treatment for achondroplasia, and BMN 307, a gene therapy for PKU.
Ms. Carole Nuechterlein joined F. Hoffmann-La Roche Ltd. in 2001 and currently serves as Head of the Roche Venture Fund. Previously, Ms. Nuechterlein served as General Counsel for SangStat, Inc. She began her career in the mergers and acquisitions group at Skadden Arps Slate Meagher & Flom.
Ms. Nuechterlein earned her B.A. from Valparaiso University and J.D. from the University of Michigan. She currently serves on the board of directors for Aligos Therapeutics, Arch Oncology, CiVi Biopharma, Lumos Pharma, Lysosomal Therapeutics, Maculogix, Mission Therapeutics, Second Genome, and Vivet Therapeutics and as an observer at C4 Therapeutics. Her previous investment and board experience includes Alios BioPharma, Allakos, Ambit Biosciences, AveXis, Envoy Therapeutics and Pharmasset.
Dr. Julia C. Owens co-founded Millendo Therapeutics in 2012 and has served as President and Chief Executive Officer since its inception. Dr. Owens has an extensive track record of building successful biopharmaceutical companies, with particular expertise in business development, strategic partnerships and mergers and acquisitions. Prior to co-founding Millendo, she served as senior vice president, corporate development and strategy at Lycera Corp., where she led the partnering process that culminated in a major research partnership with Merck & Co. and the acquisition of a new platform discovery program for the company. Prior to Lycera, Dr. Owens served as head of business development at QuatRx Pharmaceuticals where she established key strategic partnerships, including one with Shionogi for the approved drug, Osphena®. Earlier in her career, Dr. Owens worked at Tularik Inc. (now Amgen San Francisco) where she led partnering for oncology and immunology as well as technology acquisition efforts, after beginning her biotech business career at the University of California, San Francisco Office of Technology Management.
Dr. Owens serves on the Board of Directors for the Biotechnology Innovation Organization (BIO) on its Health Section and Emerging Companies Section Governing Boards, the Leadership Council for the Life Sciences Institute at the University of Michigan, the Investment Advisory Board for the Michigan Biomedical Venture Fund and the Millendo Therapeutics Board of Directors.
Dr. Owens holds a Ph.D. in biochemistry from the University of California, San Francisco and a B.S. in chemistry and B.A. in molecular and cellular biology from the University of California, Berkeley.